Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Sales (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Return on Sales for 11 consecutive years, with 22.41% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales changed N/A year-over-year to 22.41%; the TTM value through Mar 2026 reached 4708.15%, changed N/A, while the annual FY2025 figure was 14.2%, N/A changed from the prior year.
  • Return on Sales hit 22.41% in Q1 2026 for Crescent Biopharma, down from 141.6% in the prior quarter.
  • Across five years, Return on Sales topped out at 141.6% in Q4 2025 and bottomed at 622.52% in Q4 2022.
  • Average Return on Sales over 4 years is 262.06%, with a median of 176.9% recorded in 2022.
  • On a YoY basis, Return on Sales climbed as much as 10122635bps in 2022 and fell as far as -59808bps in 2022.
  • Crescent Biopharma's Return on Sales stood at 622.52% in 2022, then grew by 9bps to 565.27% in 2023, then surged by 125bps to 141.6% in 2025, then tumbled by -116bps to 22.41% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 22.41%, 141.6%, and 59.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.